The clinical information you need, at your fingertips.

Longer GLP-1 use was associated with progressively lower rates of knee replacement, particularly with semaglutide and tirzepatide. . .

Phase 3 MajesTEC-9 data show substantially longer remission and improved overall survival versus standard regimens in relapsed/refractory multiple myeloma. . .

Bispecific PD-1/VEGF therapy delivers a significant survival edge over tislelizumab plus chemotherapy in phase 3 trial. . .

The savings roughly offset the cost of the meals and tipped into net savings for patients with the highest-risk conditions including heart, kidney, and metabolic disease. . .

Population-wide pathogenic variant testing uncovered many women who would otherwise not qualify for intensified screening. . .

Phase 3 trial results showed improved metastasis-free survival when apalutamide was added to androgen-deprivation therapy before and after prostatectomy. . .